137 related articles for article (PubMed ID: 36323309)
1. A multi-center analysis of the impact of DA-EPOCH-R dose-adjustment on clinical outcomes of patients with double/triple-hit lymphoma.
Cortese MJ; Wei W; Cerdeña S; Watkins MP; Olson M; Jodon G; Kaiser J; Haverkos B; Hughes ME; Namoglu E; Grover NS; Snow A; Orellana-Noia V; Rainey M; Sohail M; Rudoni J; Portell C; Voorhees T; Landsburg DJ; Kamdar M; Kahl BS; Hill BT
Leuk Lymphoma; 2023 Jan; 64(1):107-118. PubMed ID: 36323309
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of lenalidomide plus dose-adjusted EPOCH-R in patients with aggressive B-cell lymphomas with deregulated MYC and BCL2.
Godfrey JK; Nabhan C; Karrison T; Kline JP; Cohen KS; Bishop MR; Stadler WM; Karmali R; Venugopal P; Rapoport AP; Smith SM
Cancer; 2019 Jun; 125(11):1830-1836. PubMed ID: 30707764
[TBL] [Abstract][Full Text] [Related]
3. Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab/R-CHOP regimens.
Zhang F; Li L; Zhang L; Li X; Fu X; Wang X; Wu J; Sun Z; Kong F; Ren L; Zhang M
Blood Lymphat Cancer; 2019; 9():33-43. PubMed ID: 31692510
[TBL] [Abstract][Full Text] [Related]
4. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study.
Dunleavy K; Fanale MA; Abramson JS; Noy A; Caimi PF; Pittaluga S; Parekh S; Lacasce A; Hayslip JW; Jagadeesh D; Nagpal S; Lechowicz MJ; Gaur R; Lucas A; Melani C; Roschewski M; Steinberg SM; Jaffe ES; Kahl B; Friedberg JW; Little RF; Bartlett NL; Wilson WH
Lancet Haematol; 2018 Dec; 5(12):e609-e617. PubMed ID: 30501868
[TBL] [Abstract][Full Text] [Related]
5. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma.
Zhang XY; Liang JH; Wang L; Zhu HY; Wu W; Cao L; Fan L; Li JY; Xu W
J Cancer Res Clin Oncol; 2019 Jan; 145(1):117-127. PubMed ID: 30327941
[TBL] [Abstract][Full Text] [Related]
6. Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
Mitrovic Z; Dujmovic D; Jaksic O; Kinda SB; Gacina P; Perisa V; Prka Z; Dreta B; Galusic D; Holik H; Pejsa V; Aurer I
Eur J Haematol; 2023 Jun; 110(6):725-731. PubMed ID: 36941738
[TBL] [Abstract][Full Text] [Related]
7. Dose-adjusted EPOCH-R is a safe and well tolerated outpatient treatment regimen in double-hit lymphoma.
Nelles R; Morris K; Scott A; Kennedy G
Intern Med J; 2023 May; 53(5):773-778. PubMed ID: 35289474
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with
Ma Q; Chang Y; Li L; Li X; Wang X; Wu J; Fu X; Sun Z; Yu H; Zhang X; Zhou Z; Nan F; Li Z; Liu X; Zhao Q; Li Y; Zhang L; Zhang M; Zhang L
Cancer Manag Res; 2019; 11():1363-1372. PubMed ID: 30809101
[TBL] [Abstract][Full Text] [Related]
9. A phase 1-2 trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen.
Karmali R; Galvez C; Hamadani M; Gordon L; Winter J; Ma S; Nelson V; Fenske TS; Shah NN; Jagadeesh D; Klein A; Helenowski I; Chen R; Mi X; Petrich A; Evens AM; Pro B
Blood Adv; 2024 Apr; 8(7):1612-1620. PubMed ID: 38237077
[TBL] [Abstract][Full Text] [Related]
10. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
11. Interferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an open-label, single-centre, phase 2 trial.
Melani C; Dowdell K; Pittaluga S; Dunleavy K; Roschewski M; Song JY; Calattini S; Kawada JI; Price DA; Chattopadhyay PK; Roederer M; Lucas AN; Steinberg SM; Jaffe ES; Cohen JI; Wilson WH
Lancet Haematol; 2023 May; 10(5):e346-e358. PubMed ID: 37011643
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
Giulino-Roth L; O'Donohue T; Chen Z; Bartlett NL; LaCasce A; Martin-Doyle W; Barth MJ; Davies K; Blum KA; Christian B; Casulo C; Smith SM; Godfrey J; Termuhlen A; Oberley MJ; Alexander S; Weitzman S; Appel B; Mizukawa B; Svoboda J; Afify Z; Pauly M; Dave H; Gardner R; Stephens DM; Zeitler WA; Forlenza C; Levine J; Williams ME; Sima JL; Bollard CM; Leonard JP
Br J Haematol; 2017 Dec; 179(5):739-747. PubMed ID: 29082519
[TBL] [Abstract][Full Text] [Related]
13. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
[TBL] [Abstract][Full Text] [Related]
14. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
David RJ; Baran A; Loh KP; Casulo C; Barr PM; Friedberg JW; Reagan PM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):781-787. PubMed ID: 30262330
[TBL] [Abstract][Full Text] [Related]
15. Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.
Bartlett NL; Wilson WH; Jung SH; Hsi ED; Maurer MJ; Pederson LD; Polley MC; Pitcher BN; Cheson BD; Kahl BS; Friedberg JW; Staudt LM; Wagner-Johnston ND; Blum KA; Abramson JS; Reddy NM; Winter JN; Chang JE; Gopal AK; Chadburn A; Mathew S; Fisher RI; Richards KL; Schöder H; Zelenetz AD; Leonard JP
J Clin Oncol; 2019 Jul; 37(21):1790-1799. PubMed ID: 30939090
[TBL] [Abstract][Full Text] [Related]
16. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.
Howlett C; Snedecor SJ; Landsburg DJ; Svoboda J; Chong EA; Schuster SJ; Nasta SD; Feldman T; Rago A; Walsh KM; Weber S; Goy A; Mato A
Br J Haematol; 2015 Aug; 170(4):504-14. PubMed ID: 25907897
[TBL] [Abstract][Full Text] [Related]
17. Low-intensity therapy in adults with Burkitt's lymphoma.
Dunleavy K; Pittaluga S; Shovlin M; Steinberg SM; Cole D; Grant C; Widemann B; Staudt LM; Jaffe ES; Little RF; Wilson WH
N Engl J Med; 2013 Nov; 369(20):1915-25. PubMed ID: 24224624
[TBL] [Abstract][Full Text] [Related]
18. No Evident Prognostic Benefit of Statin Use in Diffuse Large B-Cell Lymphoma Patients with Unfavorable Disease Features Treated with R-DA-EPOCH.
Sabljic A; Sedinic Lacko M; Kusec R; Pejsa V; Lucijanic M
Pharmacology; 2022; 107(11-12):623-627. PubMed ID: 36228590
[TBL] [Abstract][Full Text] [Related]
19. R-CHOP Vs DA-EPOCH-R for Double-Expressor Lymphoma: A University of California Hematologic Malignancies Consortium Retrospective Analysis.
Othman T; Penaloza J; Zhang S; Daniel CE; Gaut D; Oliai C; Brem EA; Baweja A; Ly J; Reid J; Pinter-Brown L; Lee M; Abdulhaq H; Tuscano J
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e947-e957. PubMed ID: 35858904
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on chemotherapy for the management of double-hit lymphoma.
Al-Juhaishi T; Mckay J; Sindel A; Yazbeck V
Expert Opin Pharmacother; 2020 Apr; 21(6):653-661. PubMed ID: 32066288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]